Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 3 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × cositecan × Clear all
NCT00097903 2020-03-12

Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

BioNumerik Pharmaceuticals, Inc.

Phase 1 Completed
32 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT00014521 2008-07-24

Karenitecin in Treating Patients With Recurrent Malignant Glioma

National Cancer Institute (NCI)

Phase 1 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡